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Abstract: Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both 
histone and non-histone target resulting in epigenetic reprogramming and altered activity, 
stability and localisation of non-histone proteins to ultimately mediate diverse biological 
effects on cancer cells and their microenvironment. Clinical trials have demonstrated single 
agent HDACi to have activity in hematological malignancies, in particular T-cell 
lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based 
on pre-clinical data are being employed with significant success due to their excellent side 
effect profile. Correlative studies will provide valuable information on the sub-groups of 
patients more likely to respond or be resistant to HDACi therapy, while long-term 
monitoring for toxicities is also needed. 
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1. Introduction  
Histones are a family of proteins that interact with DNA resulting in DNA being wound around a 
histone octameric core within a nucleosome. The organization of chromatin affects key molecular 
processes such as gene transcription, DNA repair, recombination and replication [1], and multiple post 
translational modifications occur at specific sites within the histone N-termini, regulating chromatin 
structure and DNA accessibility. The histone deacetylase (HDAC) enzymes are a multi-class, multi-
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member family that affect chromatin conformation via deacetylation of ε-N-acetyl lysine amino acids 
on histone proteins [2]. They are highly conserved and are classified based by their homology to yeast 
enzymes [3]. A total of 18 HDACs have been described, divided into four general classes. Class I 
includes the HDACs 1, 2, 3 and 8, located within the cell nucleus; class IIa (with one catalytic site) 
includes the HDACs 4, 5, 7 and 9; class IIb (with two catalytic sites) includes the HDACs 6 and 10; 
and the class IV HDAC, HDAC 11. Class IIa, IIb and IV HDACs shuttle between the cell cytoplasm 
and nucleus. Class III HDACs consist of the NAD+-dependent sirtuin family 1 to 7 [4]. HDACs work 
in opposition to histone acetylase transferase enzymes (HAT), which result in net gain in lysine 
acetylation. HDACs and HATs control the degree of histone acetylation and deacetylation which, in 
concert with other epigenetic changes such as methylation, phosphorylation and sumoylation, 
facilitates open or closed chromatin states. Increased acetylation of histones is associated with open 
DNA and increased transcription, and deacetylation with transcriptional repression [5]. Epigenetic 
changes play a fundamental role in cancer onset and progression, with hypermethylation of tumor 
suppressor gene promoter sites and resultant transcriptional silencing, occurring in conjunction with 
global DNA hypomethylation commonly seen in cancer cells [6]. These epigenetic changes are 
reversible and thus valid targets for anti-cancer therapy [7]. 
2. HDAC Inhibitors (HDACi) 
The HDACi’s are a new class of structurally diverse, targeted anti-neoplastic agents. These drugs 
are all able to bind to the catalytic pockets of class I, II and IV HDACs [8], and can be subdivided into 
six groups based on their highly disparate chemical structures. It is unknown whether these structural 
differences result in different capacities to hyperacetylate lysine residues on histone and non-histone 
targets, and pharmacokinetic properties, or if targeting HDAC isotypes using class I selective drugs 
such as mocetinostat or entinostat results in responses equivalent to pan-HDACi, with a potential 
reduction in toxicity [9-11]. Moreover, acetylation of non-histone proteins such as P53 by these drugs 
results in alterations in their function, and downstream effects on tumor cells [8]. Nevertheless, despite 
these unknowns these drugs have rapidly entered the clinical arena and shown efficacy in multiple 
malignancies, in particular hematological cancers. Given the increasing and large number of HDACi in 
pre-clinical and clinical development, breadth of depth of pre-clinical and clinical studies in a huge 
number of diseases, for the purposes of succinctness this review will concentrate upon the clinical 
studies of the more developed HDACi in hematological malignancies alone. 
3. Vorinostat 
Vorinostat (suberoylanilide hydroxamic acid, SAHA), a hydroxamic acid derivative, is an analogue of 
trichostatin A and has pan-HDACi effects. The US Food and Drug Administration (FDA) approved 
vorinostat for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) [12]. The 
therapeutic use of both intravenous and oral formulations of vorinostat came to light with the combined 
reporting of separate phase I studies in patients with advanced malignancies [13]. At a variety of dosing 
intensities, responses were observed in five patients with Hodgkin lymphoma (HL), diffuse large B-cell 
lymphoma (DLBCL), and CTCL. Discrepancies in both C-max and area under the curve (AUC) were 
evident between the methods of administration, although failed to account for the greater hematologic Pharmaceuticals 2010, 3 
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toxicity seen with oral vorinostat or the increased fatigue, infection and diarrhea seen in hematological 
patients generally. Increased histone hyperacetylation, a biomarker for the effects of HDAC inhibition, 
was seen in peripheral blood mononuclear cells (PBMCs) by two hours post treatment, with higher doses 
resulting in a longer duration of hyperacetylation. Histone hyperacetylation was also evident in tumor 
biopsies, although no correlation between hyperacetylation and response was seen, suggesting potentially 
numerous other targets affecting response which may impact on anti-tumor efficacy. A subsequent phase 
II study focusing on DLBCL showed only few responders, with one complete remission (CR), and one 
sustained stable disease (SD) [14]. A phase I study performed in patients with low grade lymphoma, 
reported two CRs/unconfirmed (CRu) and one partial response (PR) among patients with follicular 
lymphoma, and one CRu in a patient with mantle cell lymphoma, with one response maintained for 18 
months [15]. Responses in low grade lymphoma were confirmed in a phase II study involving 37 
patients, most with follicular lymphoma, with six patients achieving a CR and four PR, for an overall 
response rate (ORR) of 29%. There was a median progression free survival (PFS) of seven months, with 
five patients remaining on study for more than 18 months [16]. 
Following the surprising response of a patient with CTCL to vorinostat, 33 patients with 
relapsed/refractory CTCL were accrued to a single centre phase II dose finding study [17]. The ORR 
was 24%, with a reduction in pruritus seen in 58% of patients, allowing evaluation in a phase IIb 
multi-centre trial. This non blinded single arm pivotal trial in CTCL assessed responses by changes in 
overall skin disease score using a modified severity-weighted assessment tool (mSWAT; ref. 20). The 
objective response rate was 30% in 74 patients, with the most common toxicities gastrointestinal and 
hematological abnormalities, generally mild to moderate in severity.  Skin biopsies taken prior to 
treatment to identify predictors of vorinostat response [18], suggested nuclear accumulation of signal 
transduction and activators of transcription (STAT) 1 (STAT1) and phosphorylated STAT3 in 
malignant T cells on immuno-histochemistry correlated with a poor response to treatment. This may 
potentially allow a routine immunostain to predict clinical responses to vorinostat. Similarly a recent 
paper identified levels of HR23B, which is involved in the transport of ubiquitinated proteins to the 
proteasome, as a marker for response to vorinostat. Preclinical work was validated using immuno-
histochemistry on skin biopsies from patients treated with vorinostat on study, with high HR23B levels 
predicting response [19]. 
A dose escalating study of vorinostat in 41 patients with acute myeloid leukemia (AML) reported 
four patients (17%) to respond, including two who achieved a CR [20]. Grade 3/4 adverse events were 
predominantly fatigue, diarrhea, and thrombocytopenia. Rapid histone hyperacetylation was observed 
in PBMC’s and bone marrow in all patients, with levels returning to baseline during breaks in 
treatment. Gene expression analysis of PBMC’s validated previous pre-clinical work suggesting 
vorinostat efficacy may in part depend on the generation of reactive oxygen species (ROS) [21]. Genes 
associated with clinical resistance to vorinostat in this small study included overexpression of p21- and 
p53-responsive genes [22]. A phase II study failed to confirm the efficacy of single agent vorinostat in 
refractory AML, with more than half of 37 patients receiving fewer than two treatment cycles, and 
only one patient responding to treatment albeit for greater than one year [23]. Combination studies 
have been initiated, with the addition of both induction and maintenance vorinostat with idarubicin 
(Ida) and cytarabine (ara-C) as front line therapy in elderly patients with AML or higher risk 
myelodysplastic syndrome (MDS). From 45 evaluable patients there was no increase in toxicity Pharmaceuticals 2010, 3 
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compared to the historical comparator of idarubicin and cytarabine alone, and despite short follow up, 
the disease free survival (DFS) was a promising 9.5 months. Correlative studies showed LC-3, a 
marker of autophagy, ROS activation
 and NF-Kappaβ signalling to be upregulated [24]. 
Despite the lack of clinical studies of single agent vorinostat in multiple myeloma (MM), preclinical 
studies in combination with the proteasome inhibitor bortezomib has demonstrated significant synergy in 
the induction of apoptosis by plasma cells [25]. Mechanisms of bortezomib resistance include misfolded 
proteins accumulating following proteasome inhibition utilising alpha-tubulin, to form an aggresome in 
malignant plasma cells. HDACi induced tubulin hyperacetylation prevents aggresome formation, 
resulting in an increase in apoptosis [26]. More recently, bortezomib has been shown to down-regulate 
the expression of class I HDACs in MM cells at the transcriptional level, also resulting in an increase in 
histone hyperacetylation [27,28]. Phase I studies suggest the combination to be well tolerated, with near 
maximum single agent doses of both drugs deliverable. From twenty-three heavily pre-treated patients 
the overall response rate was 42%, including three partial responses among nine patients previously 
refractory to bortezomib. Despite this, protein levels of NF-kappaB, IkappaB, acetylated tubulin, and 
p21
CIP1 on plasma cells at baseline and day 11 showed no correlation with clinical response [29]. 
4. Romidepsin 
Romidepsin (depsipeptide) becomes an active compound following reduction of a disulphide bond 
following cell entry, becoming capable of preferentially interacting with the zinc in the active site of the 
HDAC class I enzymes. Romidepsin is still able to inhibit class II enzymes, but to a lesser degree [30]. The 
first published study in haematological malignancies undertaken with romidepsin was performed in 
patients with chronic lymphocytic leukemia (CLL) and AML patients, initiated with an goal to increase 
histone acetylation of by 100% in vitro [31]. Despite the lack of formal responses anti-leukemic effects 
were noted with reductions in peripheral leukemic cell number, with one patient experiencing tumour lysis.  
Following responses in four patients with T-cell lymphoma in a phase I trial [32], two large groups 
have investigated romidepsin in phase II trials. On the basis of data from these multi-centre, single-arm 
studies, of a total of 167 patients, romidepsin has recently received FDA approval for the treatment of 
refractory CTCL at a dose of 14 mg/m
2 as a 4-hour infusion on days 1, 8, and 15 of a 28-day cycle 
with a starting dose of 14 mg/m2. Similar response rates were seen both studies (34% and 35% 
respectively), with a CR rate of 6% in both. The median response was 15.1 months and 11 months. 
Notably CRs were achieved even in patients with the leukemic form of CTCL, Sezary syndrome. 
Several patients also achieved very long durations of response, even after drug cessation, with one 
patient in a CR off therapy after 63 months [33,34]. Unlike vorinostat, correlative studies on samples 
from 61 patients from an NCI study did show an association of pharmacological alterations in genetic 
targets with response to treatment. Increases in the levels of histone acetylation and ABCB1 gene 
expression in PBMCs, as well as ABCB1 gene expression in tumor biopsy samples increased in all 
samples following romidepsin treatment. Moreover, the degree of histone acetylation in PBMCs at 24 
hours did loosely correlate with the C-max and area under the curve, and was strongly associated with 
clinical response [35]. Microarray analysis revealed specific CTCL signature genes (which have been 
recognized to differentiate between Sezary syndrome and aleukemic forms of CTCL) were reversed 
following romidepsin treatment [36], suggesting either effective peripheral blood tumor elimination  
or differentiation.  Pharmaceuticals 2010, 3 
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Similarly impressive single agent activity has been reported in patients with relapsed or refractory 
peripheral T-cell lymphoma (PTCL), with an ORR of 33% as a single agent in 46 patients. Responses 
included five CR’s and 10 PR’s with a median duration of response for all patients of 9 months. 
Responses appeared to be independent of prior therapy and subtype of PTCL [37].  
Following concern over alterations in patient ECG traces, in particular QTc prolongation, recorded 
after romidepsin treatment, intensive electrocardiogram and ejection fraction monitoring were initiated 
in clinical trials involving this drug. A cardiac safety monitoring plan agreed with the FDA reported on 
4909 ECGs from
 110 patients in three clinical studies. Increases in the QTcF peaked 2 hours post 
infusion and returned to normal by 24 hours, with no patient
 increasing QTcF by more than 60 msec 
from baseline or having an absolute QTcF
  > 480 msec [38]. Therefore, careful patient selection, 
excluding those with a significant cardiac history, and the use of aggressive electrolyte replacement 
would appear to minimize any risk of QTc prolongation. Other common adverse events reported in the 
phase II studies were nausea, fatigue, vomiting, and cytopenias.  
Single-agent romidepsin has been trialled in MM, with no clinical responses, although some 
patients obtained SD with demonstrable decreases in monoclonal protein [39]. Following a similar 
rationale to the vorinostat/bortezomib studies, an ongoing Australian phase I/II trial is examining the 
combination of induction and maintenance romidepsin in conjunction with bortezomib and 
dexamethasone. Of 22 patients treated to date, there has been four CR, two very good partial responses 
(VGPR), six PR, five minimal responses (MR), and one SD. Patients refractory to prior bortezomib 
have also shown responses [40].  
5. Panobinostat 
Panobinostat (LBH589) is a structurally novel cinnamic hydroxamic acid analogue, with both 
intravenous and oral formulations. The original two-arm, dose-escalation phase IA/II used a seven 
consecutive day dosing schedule of intravenous panobinostat study in patients with advanced 
hematological malignancies. Following the detection of asymptomatic grade 3QTcF prolongation in 
four out of 15 patients resulted in premature discontinuation of the study. During later drug 
development it became clear that drug scheduling greatly influenced QTcF effects, and all subsequent 
studies have since used intermittent dosing schedules with minimal cardiac complications [41].  
The first study of oral panobinostat on a Monday, Wednesday, and Friday (MWF) schedule on a 
dose escalating weekly and alternate weekly treatments enrolled 10 CTCL patients, with two achieving 
CR, four PR, two SD, and two patients PD [42]. The MTD was determined to be 20 mg for the MWF 
every week schedule due to dose-limiting diarrhea and thrombocytopenia-significantly lower than in 
other trials utilising this drug-in what appears a disease specific phenomenon. Histone acetylation 
occurred in normal PBMCs at doses of 15 mg and above for at least 72 hours in 50% of patients. Gene 
expression profiling performed on correlative skin biopsies from six patients at 0, 4, 8, and 24 hours 
post drug, showed the large majority of affected genes were down-regulated. A total of 23 genes were 
commonly up- or down-regulated in all patients, implicating cell cycle, cell proliferation, angiogenesis, 
and immune regulation as HDACi targets [43]. A phase II study of oral panobinostat delivered MWF 
in patients with refractory CTCL has enrolled 95 patients to date, with 15 demonstrating responses by 
SWAT and CT criteria [44].  Pharmaceuticals 2010, 3 
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Interim analyses of a large, ongoing, two-arm phase IA/II dose-escalation study has examined the 
role of panobinostat in several hematological diseases at multiple dose levels and weekly MWF or 
alternate weekly MWF dosing. This study has already enrolled 176 patients with doses ranging from 
20 mg to 80 mg [45]. Panobinostat increased histone acetylation in PBMCs and bone marrow core 
biopsies relative to baseline at all doses over 20 mg, however the relationship between acetylation 
status and tumor response remains unclear. If the arms of the trial are analysed by disease, impressive 
responses have seen in both myeloid and lymphoid diseases. For example, in AML, once patients were 
treated at doses at and above 40 mg MWF weekly clear anti-leukemic activity was seen in seven of 36 
evaluable patients with two CRs, one CR incomplete (CRi), and four patients with greater than 50% 
reduction in bone marrow and/or peripheral blood blasts seen.  
Results are available in twelve evaluable patients with myelofibrosis, eight of whom were transfusion 
dependent at study entry, and most had received prior treatments most commonly hydroxyurea. Nine 
patients had confirmed JAK2
V617F mutations. One previously untreated
  patient achieved a partial 
response, with an 85% reduction in spleen size, while three other patients have shown clinical 
improvement lasting ≥8 weeks including reductions
 in spleen size and transfusion independence [46]. 
These results are similar to those from another study using panobinostat for MF, with a total of 12 
patients have
 been enrolled with eight evaluable patients. Of these, two patients have attained a PR with 
one transfusion independent, with a further four patients experiencing clinical improvement [47]. 
Panobinstat demonstrated striking effects against HL, by both positron emission tomography (PET) 
and computed tomography (CT) scanning, with one out of 28 patients attaining a metabolic CR,   
16 PR, and eight SD, and one anatomical CR, nine PR, and 12 SD with two patients on therapy for 
more than 18 months. Constitutional symptoms were also relieved by the drugs, with results leading to 
the initiation of an international multicenter trial for relapsed refractory HL [45].  
Preliminary results have been reported from a phase II study in which 38 patients with MM were 
treated with oral panobinostat 20 mg MWF with modest results [48]. As with other HDACi, studies have 
been initiated combining panobinostat with bortezomib, and a phase 1b study has already enrolled 29 
patients in four cohorts with two dose levels for each drug. Fourteen responders with PR
 or better have 
already been seen in 28 evaluable patients, including four with
 immunofixation (IF) negative CR. A 
further four
 patients achieved minor responses, resulting in a 64% overall
 response rate. Again HDACi 
therapy was able to overcome prior bortezomib resistance in six of ten patients. Predominent adverse 
events were thrombocytopenia as well as other hematological abnormalities and fatigue [49]. 
There has been longstanding interest in the use of HDACi in chronic myeloid leukemia (CML), a 
disease driven by the deregulated oncogenic tyrosine kinase Bcr-Abl, primarily as Bcr-Abl is a client 
protein for the chaperone
 heat shock protein (hsp) 90. HDACi that inhibit HDAC6 are able to induce the 
acetylation of Hsp90, inhibiting association
 with client proteins, causing their subsequent degradation. 
Despite this and proof of concept in pre-clinical studies, early clinical results have not as yet borne out 
this promise. In phase I studies of panobinostat, only one patient achieving a hematological remission, 
with eradication of the T315I clone, but there were no other complete cytogenetic or molecular 
responders [50,51]. Poor outcome may relate to the low dose of 20mg MWF used in both studies, the 
TKI refractory nature of the disease. In this case, potentially the drug may be able to suppress the TKI 
resistant T315I clone and benefit patients in conjunction with standard TKI therapy. Pharmaceuticals 2010, 3 
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6. Belinostat 
Belinostat (PXD101) also belongs to the hydroxamic acid class of HDACi, and has been administered 
in a phase I study in patients with advanced B-cell malignancies as an infusion on days 1 to 5 of a 21-day 
cycle [52]. Sixteen patients were treated with disease stabilization occurring in five. Histone 
hyperacetylation of PBMC’s occurred rapidly, although was brief, with the duration related to dose.  
A phase II multi-centre trial treated 53 patients with relapsed
 PTCL and CTCL with
 the same dose 
schedule of belinostat described above.
 Five of 20 PTCL patients responded with two CRs and three 
PRs, with a median duration of response of 159 days, and a further SD in five patients. Regarding 
CTCL, four of 29 patients
 responded with two CRs and two PRs with a median duration
 of response of 
273 days, and SD in 17 pts. Improvement in pruritus was seen in seven of 14 pts with significant
 
baseline pruritis. The drug was extremely well tolerated with few grade 3/4 toxicities [53]. Studies 
using belinostat as a single agent in both MM and lymphoma have been reported with both reporting 
patients having stable disease on treatment [54,55]. 
A study in AML added escalating doses of belinostat to azacytidine for advanced myeloid 
malignancies, predominantly relapsed or refractory AML. The combination was well tolerated, and of 
21 evaluable patients there were two CRs, one PR and four with hematological improvements, most 
responders at the 1000 mg/m
2 dose level. Another study in AML added belinostat to idarubucin in 
patients with AML not able to tolerate intensive therapy with no obvious elevation in toxicity [56]. 
7. Mocetinostat 
Mocetinostat (MGCD0103) is a highly selective aminophenylbenzamide able to strongly inhibit 
HDAC classes I and IV, but with little class II effect. Due to its prolonged pharmacodynamics, the 
drug requires less frequent dosing [57]. Although development was temporarily suspended due to 
concerns over pericardial toxicity, occurring in around 4% of patients, mocetinostat has received 
orphan drug designation for HL and AML, with patients receiving the drug undergoing 
electrocardiogram and echocardiogram testing prior to initiation. Other common adverse events with 
MGCD0103 include fatigue and gastrointestinal symptoms, with little neutropenia and 
thrombocytopenia reported, albeit using protocol specific definitions of hematological toxicity [10]. 
The multi-centre phase 1 trial of oral MGCD0103 established 100 mg thrice weekly in 23 patients with 
leukemia and myelodysplastic syndromes as the maximum tolerated dose, with three patients 
responding [10]. A dose dependant acetylation of histone H3 was seen. Further studies in AML have 
used dose escalating thrice weekly mocetinostat in combination with the hypomethylating agent 5-
azacytidine. In a phase I/II study, 37 evaluable patients, there were 11 objective responses including 
four CRs, five CRs with incomplete peripheral count recovery (CRi), and two PRs. Higher response 
rates occurred in patients receiving MGCD0103 at higher doses [58]. 
A phase II trial evaluated mocetinostat in relapsed and or refractory classical HL at doses of 85 mg 
and 110 mg thrice weekly [59]. Patients were heavily pre-treated and of 21 evaluable patients in the 
110-mg cohort, two achieved CR and six PR. The PFS for the patients in CR was 270+ and 420+ days. 
Five evaluable patients treated at 85 mg, showed a degree of tumor reduction by CT, with one PR and 
two SD. Serum thymus and activation regulated chemokine (TARC) is highly expressed by Hodgkin 
Reed-Sternberg (HRS) cells and dendritic cells in the malignant lymph node and is able to provoke a Pharmaceuticals 2010, 3 
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TH2 response [60]. In-vitro observations of a reduction in TARC when HL cell lines are treated with 
vorinostat were recapitulated by the MGCD0103 clinical trial, where responses correlated well with a 
reduction in TARC levels [59]. It is not clear how the reduction in TARC is achieved and whether its 
reduction is directly related to anti-tumour efficacy. A phase II study in relapsed or refractory DLBCL 
or follicular lymphoma (FL) resulted in responses in 17 patients with DLBCL including one CR and 
three PR, with PFS for responders ranging from 168 to 336+ days. Interestingly, five patients with 
DLBCL with SD had PFS ranging from 112 to greater than 336 days [61]. Only one of 10 patients 
with FL achieved a PR. Inhibition of HDAC activity in PBMCs was seen to occur in most patients.  
A phase II clinical trial in CLL began mocetinostat at a dose of 85 mg/d, thrice weekly. All 21 
patients had previously received fludarabine, a third of which were fludarabine refractory, with the 
majority having documented adverse cytogenetics. There were no responses, even in patients receiving 
permitted dose escalation to 110 mg or the addition of rituximab after two or more cycles. Three 
patients received 110 mg and four patients received concomitant rituximab, with no improvement in 
response, despite grade 3-4 toxicities and HDAC inhibition observed in six out of nine patients on day 
8 [62]. Whether the clear anti-tumour activity of mocetinostat is unable to overcome the adverse 
characteristics of patients with 11q or 17p deletions or whether CLL is a disease generally 
unresponsive to HDACi remains to be seen.  
8. Entinostat 
Entinostat (MS-275) is a synthetic benzamide derivative HDACi which predominantly inhibits class 
I HDAC enzymes. A study of entinostat in patients with advanced refractory acute leukemia showed 
the drug to be well tolerated but did not result in any formal responses, despite 12 patients having brief 
reductions in peripheral blood blast numbers [11]. Histone and protein hyperacetylation was shown at 
all dose levels by flow cytometry but marked PK variation at all dose levels made correlation with 
drug exposure difficult. Indeed the half life was 36 hours, far longer than anticipated, while the AUC 
did not increase proportionately with drug dose.  
A phase I study combining escalating doses of both 5-azacitidine on days one to ten and entinostat 
days three and ten, was
 conducted in patients with advanced myeloid malignancies. Of 27 evaluable 
patients twelve responded, with two CRs, four PRs, and six hematological improvements.
 Responses 
occurred at all dose combinations, in patients with
 MDS, chronic myelomonocytic leukemia (CMML), 
and AML. Six clinical responders with baseline cytogenetic abnormalities had a decrease in abnormal 
metaphases, with
 four attaining cytogenetic CR [63]. Correlative studies during the first cycle showed 
no
 association between patient response and either baseline promoter methylation
 or its reversal post 
treatment in bone marrow or the CD34
+ population. Induction of histone hyperacetylation and the 
DNA
 damage–associated variant histone  -H2AX was observed in
 PBMC’s across all dose cohorts. In 
conclusion,
  methylation reversal of tumour suppressor genes during cycle 1 of therapy
  was not 
predictive of clinical response to combination “epigenetic”
 therapy [64]. 
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9. Expert Opinion 
As the more clinically developed HDACi continue to be entered into advanced phase studies, it 
must be remembered that fundamental questions remain. On the surface this group of drugs appear to 
have both a class effect in certain diseases, including T-cell lymphomas and HL, a disease with 
associated profound reactive T-cell tumour infiltrates, and consistent side effect profiles of fatigue, 
diarrhea and thrombocytopenia. Given the molecularly diverse structure of these compounds, and the 
knowledge that some compounds are more selective for certain HDACi, does this mean some HDAC 
enzyme targets are relatively superfluous; are ‘off target’ cytoplasmic targets at least as important for 
efficacy? Will selective inhibitors be shown to have more disease-targeted activity and reduced 
toxicities or quite the opposite? Given the PET responses seen in HL, these drugs may have much to 
tell us about normal T-cell development, recruitment and apoptosis. Mocetinostat is a highly isotype 
selective HDACi with clear efficacy in HL, with the implication that class I HDACs may be the most 
important target in cancer, however we have no clinical data to compare it with pan-HDACi such as 
panobinostat. Direct comparisons of clinical efficacy and biological targets would be fascinating, but 
are unlikely to occur in the clinical setting in the near future. Ultimately as more HDACi become 
approved in a variety of indications, we may end up with specific HDACi to be most commonly used 
for specific diseases. Choice would be presumably be based upon the balance of published data, 
efficacy, convenience, side effect profile, and capacity to partner other active drugs. 
10. Future Perspectives 
Combination studies are a major focus for HDACi clinical development. Currently, demethylating 
agents for myeloid malignancies, and bortezomib for myeloma are the most common partner drugs 
being investigated with Phase III studies underway. Phase II studies in combination with standard 
chemotherapy are underway for lymphoma (Hodgkin, B-cell, T-cell), firstly in the setting of relapsed 
disease but will likely move to front-line strategies eventually. Maintenance therapy in minimal 
residual disease settings is another area of investigation. Of particular interest is whether these well 
tolerated drugs are able to improve responses and survival times in elderly patients unable to tolerate 
intensive treatments.  
Extensive pre-clinical data exists for a multitude of other compounds including monoclonal 
antibodies, tyrosine kinase inhibitors, mTOR inhibitors and BH3 mimetics, so conceivably numerous 
combination studies will be undertaken for many years to come [75].  
Despite the barrage of biomarker data demonstrating these drugs are biologically active, such as 
histone hyperacetylation, further correlative studies remain essential. It may be that specific 
cytogenetic or molecularly defined sub-groups of patients or tumor HDAC expression can predict for 
general or specific HDACi response or resistance. Lastly, despite their apparent excellent toxicity 
profile, these drugs affect the expression of large parts of the genome in both normal and transformed 
tissues, meaning that long-term monitoring of toxicities is essential, with potential areas of concern 
lymphocyte, hematopoietic and hormonal function, as well as viral reactivation.  
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